Physician profile
John E Tapp
NPI 1811986326
$10,806.15
in general payments reported to CMS, 2019-2025
51 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $1,071 · 2021: $1,988 · 2022: $1,266 · 2023: $1,807 · 2024: $2,020 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,036.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,777.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,268.58 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,202.38 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $808.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $507.03 | 2019-2025 | |
| Amgen INC. | $497.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.36 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $449.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $424.76 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $334.33 | 2019-2023 | Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $253.62 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $224.75 | 2020-2022 | |
| Amarin Pharma, INC. | $215.73 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.40 | 2019-2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $154.11 | 2021-2025 | Gvoke Hypopen |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.